Strona główna・Stock List・TG Therapeutics Inc

TG Therapeutics Inc

Open

SectorHealthcare

45.96 -11.27

Buy Sell

Overview

Share price change

24h

Current

Min

45.75

Max

51.8

Key metrics
By Trading Economics
Income	-3.3M 20M
Sales	12M 205M
P/E Sector Avg	19.493 64.641
EPS	0.18
Profit margin	9.651
Employees	399
EBITDA	-24M 28M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+22.74% upside

Dividends
By Acuity
Next Earnings	3 sie 2026

Market Stats
By TradingEconomics
Market Cap	3.1B 8.5B
Previous open	57.23
Previous close	45.96

News Sentiment

By Acuity

17%

83%

24 / 340 Ranking in Healthcare

TG Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 lip 2026, 23:16 UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

30 lip 2026, 23:56 UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

29 lip 2026, 15:52 UTC

Social Media

News

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

28 lip 2026, 19:56 UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

27 lip 2026, 19:07 UTC

Social Media

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

24 lip 2026, 23:21 UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

23 lip 2026, 23:22 UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

22 lip 2026, 23:31 UTC

TG Therapeutics Inc shares declined in after-market trading, reflecting a shift toward the lower end of its one-month trading range amid broader market pressures.

21 lip 2026, 22:21 UTC

TG Therapeutics shares are higher in after-market trading, tracking broader market gains following positive earnings from General Motors and 3M.

20 lip 2026, 23:22 UTC

TG Therapeutics shares are higher in after-market trading, recovering from a prior dip despite broader market pressures and four consecutive sessions of declines.

Peer Comparison

Price change

TG Therapeutics Inc Forecast

Price Target

By TipRanks

22.74% upside

12 Months Forecast

Average 63.86 USD 22.74%

High 86 USD

Low 20 USD

Based on 7 Wall Street analysts offering 12 month price targets forTG Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to TG Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

24 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.